FXR Agonist Compounds Modulating Lipid Profiles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia and related diseases, such as atherosclerosis and diabetes, lack potent, efficacious, and selective farnesoid X receptor (FXR) agonists that can effectively modulate plasma lipid profiles and insulin sensitivity.
Innovation Solution
Development of novel compounds with specific structural formulas that act as FXR agonists, capable of lowering total cholesterol, LDL cholesterol, triglycerides, and raising HDL levels, while sensitizing insulin production in response to glucose, thereby treating FXR-mediated conditions like dyslipidemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for dyslipidemia, then current therapy options are available, but they lack potency, efficacy, and selectivity as FXR agonists
Solution Approach 1:
The patent employs parameter changes by systematically varying structural parameters of the compound molecules (substituents on the core structure, ring sizes, linker types) to optimize both FXR binding affinity (potency) and selectivity. This is achieved through structure-activity relationship (SAR) studies where specific molecular parameters are modified to enhance therapeutic effectiveness while maintaining selectivity for FXR over other nuclear receptors.
2Reliability
If novel FXR agonist compounds are developed, then potent and efficacious treatment is achieved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the FXR agonist compound into distinct functional modules: a core structure (e.g., indole, benzofuran, pyridine rings), substituent groups (R1-R6), and linker regions. This modular segmentation allows for systematic optimization of potency and selectivity while maintaining a manageable structural framework that can be synthesized through stepwise chemical reactions.
3Adaptability or versatility
If current dyslipidemia treatments are used, then existing therapy options are maintained, but they fail to effectively modulate plasma lipid profiles and insulin sensitivity
Solution Approach 1:
The patent achieves universality by designing FXR agonist compounds that simultaneously address multiple metabolic parameters: they modulate plasma lipid profiles (lowering LDL, VLDL, and triglycerides while raising HDL) and improve insulin sensitivity. This multi-functional approach is accomplished through selective activation of FXR, which regulates multiple genes involved in lipid metabolism and insulin signaling pathways, providing comprehensive treatment for dyslipidemia and related metabolic disorders.
Data Source
AI summary
Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.